参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Breast Cancer Version 1.2019-March 14,2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed.,2017).
3.Bartelink H,Maingon P,Poortmans P,et al.Whole-breast irradiation with or without a boost for patients treated with breastconserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.Lancet Oncol 2015, 16: 47-56.
4.Louie RJ,Tonneson JE,Gowarty M,et al.Complete blood counts,liver function tests,and chest x-rays as routine screening in earlystage breast cancer: value added or just cost? Breast Cancer Res Treat 2015.
5.Moore HC,Unger JM,Phillips KA,et al.Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.N Engl J Med 2015, 372: 923-932.
6.Oktay K,Turan V,Bedoschi G,et al.Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.Journal of Clinical Oncology 2015, 33: 2424-2429.
7.Brothers JM,Kidwell KM,Brown RK,et al.Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence.Breast Cancer Res Treat 2016, 155: 395-403.
8.Rocha RD,Girardi AR,Pinto RR, et al.Axillary ultrasound and fine-needle aspiration in preoperative staging of axillary lymph nodes in patients with invasive breast cancer.Radiol Bras 2015, 48: 345-352.
9.Whelan TJ,Olivotto IA,Parulekar WR,et al.Regional nodal irradiation in early-stage breast cancer.N Engl J Med 2015, 373: 307-316.
10.Killelea BK,Yang VQ,Mougalian S,et al.Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.J Am Coll Surg 2015, 220: 1063-1069.
11.Sparano JA,Gray RJ,Makower DF,et al.Prospective validation of a 21-gene expression assay in breast cancer.New England Journal of Medicine 2015, 373: 2005-2014.(https://www.daowen.com)
12.Francis PA,Regan MM,Fleming GF,et al.Adjuvant ovarian suppression in premenopausal breast cancer.N Engl J Med 2015, 372: 436-446.
13.Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer.N Engl J Med 2015, 372: 134-141.
14.Gnant M,Pfeiler G,Dubsky PC,et al.Adjuvant denosumab in breast cancer(ABCSG-18): a multicentre,randomised, double-blind,placebo-controlled trial.Lancet 2015, 386: 433-443.
15.Ellis MJ,Llombart-Cussac A,Feltl D,et al.Fulvestrant 500 mg versus anastrozole1mg for the first-Line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study.J Clin Oncol 2015, 33: 3781-3787.
16.Finn RS,Crown JP,Lang I,et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative,advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.Lancet Oncol 2015, 16: 25-35.
17.Kaufman PA,Awada A,Twelves C,et al.Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.J Clin Oncol 2015, 33: 594-601.
18.Sagara Y,Freedman RA,Vaz-Luis I,et al.Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study.J Clin Oncol 2016, 34: 1190-1196.
19.Brothers JM,Kidwell KM,Brown RK,et al.Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence.Breast Cancer Res Treat 2016, 155: 395-403.
20.Pilewskie M,Olcese C,Eaton A,et al.Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation.Ann Surg Oncol 2014, 21: 1552-1560.
21.Moffat R,Guth U.Preserving fertility in patients undergoing treatment for breast cancer: current perspectives.Breast Cancer(Dove Med Press)2014, 6: 93-101.